Allarity Therapeutics partners with Lonza to manufacture Dovitinib

pharmafile | September 23, 2021 | News story | Business Services  

Allarity Therapeutics, a clinical-stage precision medicine company, has announced its collaboration with biopharma partner Lonza to manufacture dovitinib. Dovitinib targets metastatic renal cell carcinoma (RCC) with other potential uses in liver cancer, breast cancer and various solid tumours.

The agreement between the two companies aims to commence manufacturing of dovitinib in 2022, and will be brought to the market following Allarity’s need for regulatory approvals and protocol.   

Dovitinib is a pan-tyrosine kinase inhibitor which targets fibroblast growth factor receptor, vascular endothelial growth factor receptor, and other receptor tyrosine kinases.

CEO of Allarity, Steve Carchedie, commented: “Entering this agreement with Lonza is an important step in our long-term preparations to take dovitinib towards commercialisation. Allarity now has a robust agreement covering the production and ongoing supply of dovitinib that we will need in the years to come.”

Lonza, founded in the Swiss Alps in 1897, is a global partner to the pharmaceutical, biotech and nutrition markets. They will use the agreement to leverage its capabilities for commercial manufacturing of small-molecules and oral solid dosage forms, to provide Allarrity with cGMP compliant drug product supply and support for commercialisation. Allarity will also leverage Lonza’s global network, technical capabilities, and integrated solution covering both drug substance and drug product.

Christian Dowdeswell, VP and Global Head, Commercial Development – Small Molecules, Lonza, added: “Our collaboration with Allarity Therapeutics demonstrates our commitment to supporting companies with their development pipeline. Our unique and comprehensive set of capabilities supporting drug substance through to drug product development and manufacturing enable Allarity to focus on dovitinib commercialisation.”

Stockholm-based Allarity Therapeutics develops drugs for personalised cancer treatment, guided by its drug response predictor technology, the DRP platform. Allarity uses its drug specific DRP to select patients who, by the genetic signature of their cancer, have a higher likelihood of responding to the specific. The company currently has a portfolio of six drug candidates used for treating cancer.

Lina Adams


Related Content

No items found

Latest content